Deal Library / Pharma BD Deal Intelligence

Pharma Deals of 2001

The Pharma Closeout tracks 33 deals, $56.4B in disclosed deal value, 30 with a post-close Outcome Score for the year 2001.

Median Critic Score: 75  ·  Median Outcome Score: 51

Best outcome: Abbott Laboratories / Knoll Pharmaceutical Company (BASF Pharma) (100)  ·  Weakest outcome: Hercules Development Group / Astralis LLC (9)

All 33 deals

• Abbott Laboratories / Knoll Pharmaceutical Company (BASF Pharma) — 2001 · $6.9B · Worked — the deal delivered on its rationale.
• Vertex Pharmaceuticals Incorporated / Aurora Biosciences Corporation — 2001 · $592M · Worked — the deal delivered on its rationale.
• Amgen Inc. / Immunex Corporation — 2001 · $16.0B · Worked — the deal delivered on its rationale.
• Swedish Orphan Biovitrum AB / Biovitrum — 2001 · $493M · Worked — the deal delivered on its rationale.
• Barr Laboratories Inc. / Duramed Pharmaceuticals Inc. — 2001 · $589M · Worked — the deal delivered on its rationale.
• Cephalon Inc. / Group Lafon (France) — 2001 · $450M · Worked — the deal delivered on its rationale.
• Abbott Laboratories / Vysis Inc. — 2001 · $355M · Worked — the deal delivered on its rationale.
• Inhale Therapeutic Systems Inc. / Shearwater Corporation — 2001 · $192M · Largely worked — most objectives met.
• Johnson & Johnson / ALZA Corporation — 2001 · $10.5B · Largely worked — most objectives met.
• Cephalon Inc. / Anesta Corp. — 2001 · $444M · Largely worked — most objectives met.
• Bristol-Myers Squibb Company / ImClone Systems Incorporated — 2001 · $2.0B · Largely worked — most objectives met.
• Pharmacia Corporation / Sensus Drug Development Corporation — 2001 · $65M · Largely worked — most objectives met.
• Genzyme Corporation / Novazyme Pharmaceuticals Inc. — 2001 · $138M · Mixed — partial payoff, real shortfalls.
• Lexicon Genetics Incorporated / Coelacanth Corporation — 2001 · $32M · Mixed — partial payoff, real shortfalls.
• Bristol-Myers Squibb Company / DuPont Pharmaceuticals Company — 2001 · $7.8B · Mixed — partial payoff, real shortfalls.
• King Pharmaceuticals Inc. / Bristol-Myers Squibb (Corgard/Corzide/Delestrogen/Florinef rights) — 2001 · $285M · Mixed — partial payoff, real shortfalls.
• Sangamo BioSciences Inc. / Gendaq Limited (UK) — 2001 · $40M · Underwhelmed — fell short of the thesis.
• MedImmune Inc. / Aviron — 2001 · $1.5B · Underwhelmed — fell short of the thesis.
• Shire Pharmaceuticals Group plc / BioChem Pharma Inc. — 2001 · $4.0B · Underwhelmed — fell short of the thesis.
• OSI Pharmaceuticals Inc. / Gilead Sciences (oncology assets) — 2001 · $200M · Did not work — the deal failed to deliver.
• Merck & Co. Inc. / Rosetta Inpharmatics Inc. — 2001 · $540M · Did not work — the deal failed to deliver.
• MediGene AG / NeuroVir Therapeutics Inc. — 2001 · $77M · Did not work — the deal failed to deliver.
• Celera Genomics Group / Axys Pharmaceuticals Inc. — 2001 · $173M · Did not work — the deal failed to deliver.
• Millennium Pharmaceuticals Inc. / COR Therapeutics Inc. — 2001 · $2.0B · Did not work — the deal failed to deliver.
• Xenova Group plc / Cantab Pharmaceuticals plc (UK) — 2001 · $179M · Did not work — the deal failed to deliver.
• Inhale Therapeutic Systems Inc. / Bradford Particle Design plc (UK) — 2001 · $200M · Did not work — the deal failed to deliver.
• ArQule Inc. / Camitro Corporation — 2001 · $95M · Did not work — the deal failed to deliver.
• Sequenom Inc. / Gemini Genomics plc (UK) — 2001 · $238M · Did not work — the deal failed to deliver.
• BioTransplant Inc. / Eligix Inc. — 2001 · $55M · Did not work — the deal failed to deliver.
• Hercules Development Group / Astralis LLC — 2001 · $111M · Did not work — the deal failed to deliver.
• Aurora Biosciences Corporation / PanVera Corporation — 2001 · $86M
• Antigenics Inc. / Aronex Pharmaceuticals Inc. — 2001 · $29M
• Orchid BioSciences Inc. / AstraZeneca (Cellmark Diagnostics unit) — 2001

← Deal Library  ·  Interactive search  ·  How we score deals